View in EDS

The use of IL-1 and IL-6 inhibitors should be prioritised in Still's disease - Authors' reply.

Saved in:

Bibliographic Details
Title:	The use of IL-1 and IL-6 inhibitors should be prioritised in Still's disease - Authors' reply.
Authors:	Shen Y; Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China., Jia J; Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China., Teng J; Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China., Yang C; Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China., Hu Q; Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Electronic address: huqiongyi131@163.com.
Source:	The Lancet. Rheumatology [Lancet Rheumatol] 2025 Jul; Vol. 7 (7), pp. e460-e461. Date of Electronic Publication: 2025 May 13.
Publication Type:	Letter
Journal Info:	Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101765308 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2665-9913 (Electronic) Linking ISSN: 26659913 NLM ISO Abbreviation: Lancet Rheumatol Subsets: MEDLINE; In Process
Database:	MEDLINE Ultimate

Description
ISSN:	2665-9913
DOI:	10.1016/S2665-9913(25)00110-9